Back

Outcomes of post-acute coronary syndrome patients enrolled in a phase 2 cardiac rehabilitation program

2 September 2024 (12:00 - 12:50)
Organised by: Logo
Congress Presentation Part of: Lipids in heart disease Secondary Prevention ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Mr Mauro Moreira

Hospital Centre do Tamega e Sousa, Penafiel (Portugal)

8 More presentations in this session

Presentation thumbnail
Is the obesity paradox leading to a less stringent secondary prevention strategy in post-acute coronary syndrome patients?
Mr M. Moreira (Penafiel, PT)
Abstract Slides Video
Presentation thumbnail
Temporal trends in lipid management among Korean patients following acute myocardial infarction from 2011 to 2020
Doctor S. Oh (Gwangju, KR)
Abstract Slides Video
Presentation thumbnail
Effect of triglycerides on cardiovascular risk in patients with a first vs. recurrent acute coronary syndrome
Doctor A. Cordero (Alicante, ES)
Abstract Slides Video
Presentation thumbnail
Estimate and prognosis of patients who are candidates for treatment with eicosapentaenoic acid after an acute coronary syndrome
Doctor A. Cordero (Alicante, ES)
Abstract Slides Video
Presentation thumbnail
Statin use before acute coronary syndrome and coronary risk factors, clinical presentation, interventions, and outcomes: ACC-NCDR-CathPCI Registry in India
Professor R. Gupta (Jaipur, IN)
Abstract Slides Video

Access the full session

Session thumbnail
Lipids in heart disease

The Event

Event poster

ESC Congress 2024

2 September 2024 12:00 CET
You may be interested in
thumbnail
Congress Presentation
Cardiac rehabilitation attendance and outcomes 3 years after acute coronary syndrome (ACS): Linked national data of the SNAPSHOT ACS audit
thumbnail
Congress Presentation
Improved exercise capacity and cardiac events after rehabilitation in post-acute coronary syndrome patients.
thumbnail
Congress Presentation
Impact of a cardiac rehabilitation programme on new target populations: peripheral artery disease and cerebrovascular disease

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources